Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

351.48 -9.65 (-2.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Amgen Announces $650M Expansion Of US Manufacturing Network After Trump’s Pharma Tariff Announcement ↗
Via Stocktwits
Topics Government
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
The Analyst Verdict: Amgen In The Eyes Of 8 Experts ↗
8 analysts have shared their evaluations of Amgen (NASDAQ: AMGN) during the recent three months, expressing a mix of bullish and bearish perspectives. 
Via Benzinga
News headline image
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
News headline image
How Is The Market Feeling About Amgen? ↗
 
Via Benzinga
Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug ↗
Via Stocktwits
News headline image
European Advisory Panel Recommends Two AstraZeneca Drugs For Approval ↗
AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results. 
Via Benzinga
News headline image
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron
Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity... 
Via MarketMinute
Topics Economy
News headline image
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Why Amgen (AMGN) Stock Is Trading Up Today
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.4% in the afternoon session after a European regulatory body recommended approving its drug, Uplizna, for treating a rare autoimmune disorder. 
Via StockStory
Topics Artificial Intelligence
News headline image
Friday's session: top gainers and losers in the S&P500 index ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle
The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like... 
Via MarketMinute
News headline image
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
News headline image
EMA Backs Amgen Drug For Rare Autoimmune Disorder ↗
European Medicines Agency's panel recommends expanding Amgen's Uplizna to treat IgG4-related disease, with trial data showing reduced flares and higher remission rates. 
Via Benzinga
News headline image
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. 
Via Chartmill
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill
News headline image
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
News headline image
2 Healthcare Dividend Stocks to Buy and Hold ↗
These drugmakers have competitive yields and have increased their dividends at a good clip. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
1 Cash-Producing Stock to Target This Week and 2 Facing Challenges
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis ↗
Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in moderate to severe atopic dermatitis patients. 
Via Benzinga
News headline image
Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis
From Kyowa Kirin
Via GlobeNewswire
News headline image
If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today ↗
You could have done worse -- or much better. 
Via The Motley Fool
Topics Economy
News headline image
Nvidia Just Went Quantum—And ETFs Are Scrambling To Catch Up ↗
Nvidia's $600M investment in Quantinuum highlights quantum computing's commercial evolution and may prompt new ETF strategies in the coming years. 
Via Benzinga
Topics ETFs
News headline image
Why Is Sanofi Stock Falling Thursday? ↗
William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential. 
Via Benzinga
News headline image
Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗
Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results. 
Via Benzinga
News headline image
2 Safe-and-Steady Stocks to Keep an Eye On and 1 Facing Challenges
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.